



(12) Translation of
European patent specification

(11) NO/EP 3042917 B1

NORWAY

(19) NO
(51) Int Cl.
C07K 16/18 (2006.01)
A61K 39/395 (2006.01)
A61P 25/28 (2006.01)
G01N 33/577 (2006.01)

Norwegian Industrial Property Office

(21) Translation Published 2018.06.25

(80) Date of The European Patent Office Publication of the Granted Patent 2018.02.21

(86) European Application Nr. 15196358.4

(86) European Filing Date 2011.08.09

(87) The European Application's Publication Date 2016.07.13

(30) Priority 2010.08.12, US, 373026 P

(84) Designated Contracting States: AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR

Designated Extension States: BA ME

(62) Divided application EP2603523, med inndato 2011.08.09

(73) Proprietor Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, US-USA

(72) Inventor Demattos, Ronald, c/o Eli Lilly & Company Lilly Corporate Centre, Indianapolis, Indiana 46285, US-USA
Lu, Jirong, c/o Eli Lilly & Company Lilly Corporate Center, Indianapolis, Indiana 46285, US-USA
Tang, Ying, c/o Eli Lilly & Company Lilly Corporate Center, Indianapolis, Indiana 46285, US-USA

(74) Agent or Attorney ZACCO NORWAY AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54) Title **ANTI-N3PGLU AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF**

(56) References Cited: OLIVER WIRTHS ET AL: "Pyroglutamate A-beta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases", JOURNAL OF NEURAL TRANSMISSION ; BASIC NEUROSCIENCES, GENETICS AND IMMUNOLOGY, PARKINSON'S DISEASE AND ALLIED CONDITIONS, ALZHEIMER'S DISEASE AND ADOLESCENT PSYCHIATRY RELATED DISORDERS, BIOLOGICAL PSYCHIATRY, BIOLOGICAL CHILD AND ADOLESCENT

PSYCHIAT, vol. 117, no. 1, 13 October 2009 (2009-10-13), pages 85-96, XP019783126, ISSN: 1435-1463, BRODY DAVID L ET AL: "Active and passive immunotherapy for neurodegenerative disorders.", ANNUAL REVIEW OF NEUROSCIENCE 2008 LNKD- PUBMED:18352830, vol. 31, 2008, pages 175-193, XP002660548, ISSN: 0147-006X, FRÉDÉRIQUE BARD ET AL: "Epitope and isotype specificities of antibodies to [beta]-amyloid peptide for protection against Alzheimer's disease-like neuropathology", PROC NATL ACAD SCI (US), WASHINGTON, DC; US, vol. 100, no. 4, 18 February 2003 (2003-02-18), pages 2023-2028, XP002630662, ISSN: 0027-8424, DOI: 10.1073/PNAS.0436286100, OLIVER WIRTHS ET AL: "Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, BETHESDA, MD, USA, vol. 285, no. 53, 31 December 2010 (2010-12-31), pages 41517-41524, XP002658320, ISSN: 1083-351X, DOI: 10.1074/JBC.M110.178707 [retrieved on 2010-10-22], BAYER T A ET AL: "Intraneuronal A[beta] as a trigger for neuron loss: Can this be translated into human pathology?", BIOCHEMICAL SOCIETY TRANSACTIONS, PORTLAND PRESS LTD, GB, [Online] vol. 39, no. 4, 1 January 2011 (2011-01-01), pages 857-861, XP008142494, ISSN: 0300-5127, DOI: DOI:10.1042/BST0390857, WILCOCK DONNA M ET AL: "Passive immunotherapy against A[beta] in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage", JOURNAL OF NEUROINFLAMMATION, BIOMED CENTRAL LTD., LONDON, GB, vol. 1, no. 1, 8 December 2004 (2004-12-08), page 24, XP021010076, ISSN: 1742-2094, DOI: 10.1186/1742-2094-1-24, US-A1- 2010 021 478, US-B1- 7 122 374, LUO F ET AL: "P2-304: MRI detection and time course of cerebral microhemorrhages during Abeta antibody treatment in living APP transgenic mice", ALZHEIMER'S & DEMENTIA: THE JOURNAL OF THE ALZHEIMER'S ASSOCIATION, ELSEVIER, NEW YORK, NY, US, vol. 4, no. 4, 1 July 2008 (2008-07-01), page T461, XP023174303, ISSN: 1552-5260, DOI: 10.1016/J.JALZ.2008.05.1381 [retrieved on 2008-07-01], RACKE MARGARET M ET AL: "Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.", THE JOURNAL OF NEUROSCIENCE : THE OFFICIAL JOURNAL OF THE SOCIETY FOR NEUROSCIENCE 19 JAN 2005 LNKD- PUBMED:15659599, vol. 25, no. 3, 19 January 2005 (2005-01-19), pages 629-636, XP002660549, ISSN: 1529-2401, WO-A2-2006/036291

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

- 5 **1.** Humant konstruert anti-N3pGlu A β -antistoff omfattende en variabel
lettkjederegion (LCVR) og en variabel tungkjederegion (HCVR), hvori LCDR1 er
K SX1X2SLLYSRX3KTYLN (SEQ ID NO: 51), LCDR2 er AVSKLX4S (SEQ ID NO:
52), LCDR3 er VQGTHYPFT (SEQ ID NO: 5), og HCDR1 er GYX5FTX6YYIN (SEQ
ID NO: 53), HCDR2 er WINPGSGNTKYNEKFKG (SEQ ID NO: 8) og HCDR3 er
EGX7TVY (SEQ ID NO: 54), hvori X1 er S eller T; X2 er Q eller R, X3 er G eller S,
X4 er D eller G, X5 er D eller T, X6 er R eller D, og X7 er I, T, E eller V.
- 10
- 2.** Farmasøytisk sammensetning omfattende det humane konstruerte antistoffet
ifølge krav 1 og et farmasøytisk akseptabelt bærestoff, fortynningsmiddel eller
hjelpstoff.
- 15
- 3.** Humant konstruert antistoff eller antigenbindende fragment derav ifølge krav
1 eller en farmasøytisk sammensetning ifølge krav 2 for anvendelse i terapi.
- 4.** Humant konstruert antistoff eller antigenbindende fragment derav ifølge krav
1 eller en farmasøytisk sammensetning ifølge krav 2, for anvendelse i
20 behandlingen av en tilstand valgt fra gruppen bestående av klinisk eller
preklinisk Alzheimers sykdom, prodromal Alzheimers sykdom, Downs syndrom
og klinisk eller preklinisk cerebral amyloid angiopati (CAA), omfattende å
administrere til et menneske med behov for dette det humane konstruerte
antistoffet ifølge krav 1.
- 25
- 5.** Humant konstruert antistoff eller antigenbindende fragment derav ifølge krav
1 eller en farmasøytisk sammensetning ifølge krav 2 for anvendelse i
behandlingen av klinisk eller preklinisk Alzheimers sykdom.